These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Restoring tumor immunogenicity with dendritic cell reprogramming. Zimmermannova O; Ferreira AG; Ascic E; Velasco Santiago M; Kurochkin I; Hansen M; Met Ö; Caiado I; Shapiro IE; Michaux J; Humbert M; Soto-Cabrera D; Benonisson H; Silvério-Alves R; Gomez-Jimenez D; Bernardo C; Bauden M; Andersson R; Höglund M; Miharada K; Nakamura Y; Hugues S; Greiff L; Lindstedt M; Rosa FF; Pires CF; Bassani-Sternberg M; Svane IM; Pereira CF Sci Immunol; 2023 Jul; 8(85):eadd4817. PubMed ID: 37418548 [TBL] [Abstract][Full Text] [Related]
3. Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors. Rosa FF; Pires CF; Zimmermannova O; Pereira CF Bio Protoc; 2020 May; 10(10):e3619. PubMed ID: 33659292 [TBL] [Abstract][Full Text] [Related]
4. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
6. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Montoya M; Collins SA; Chuntova P; Patel TS; Nejo T; Yamamichi A; Kasahara N; Okada H Neuro Oncol; 2024 Aug; ():. PubMed ID: 39115195 [TBL] [Abstract][Full Text] [Related]
7. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Montoya M; Collins SA; Chuntova P; Patel TS; Nejo T; Yamamichi A; Kasahara N; Okada H bioRxiv; 2024 Apr; ():. PubMed ID: 38617245 [TBL] [Abstract][Full Text] [Related]
8. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism. Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946 [TBL] [Abstract][Full Text] [Related]
9. A New Frontier in Tumor Eradication: Harnessing Chronis C Cell Reprogram; 2024 Oct; 26(5):132-134. PubMed ID: 39387283 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation. Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602 [TBL] [Abstract][Full Text] [Related]
11. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. Bodey B; Bodey B; Kaiser HE In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303 [TBL] [Abstract][Full Text] [Related]
12. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Nestle FO; Burg G; Fäh J; Wrone-Smith T; Nickoloff BJ Am J Pathol; 1997 Feb; 150(2):641-51. PubMed ID: 9033277 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Dolan BP; Gibbs KD; Ostrand-Rosenberg S J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172 [TBL] [Abstract][Full Text] [Related]
15. Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. Linde MH; Fan AC; Köhnke T; Trotman-Grant AC; Gurev SF; Phan P; Zhao F; Haddock NL; Nuno KA; Gars EJ; Stafford M; Marshall PL; Dove CG; Linde IL; Landberg N; Miller LP; Majzner RG; Zhang TY; Majeti R Cancer Discov; 2023 May; 13(5):1164-1185. PubMed ID: 36856575 [TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
17. Effects of Friend Virus Infection and Regulatory T Cells on the Antigen Presentation Function of B Cells. Moore TC; Messer RJ; Gonzaga LM; Mather JM; Carmody AB; Bayer W; Littwitz-Salomon E; Dittmer U; Hasenkrug KJ mBio; 2019 Jan; 10(1):. PubMed ID: 30670616 [TBL] [Abstract][Full Text] [Related]
19. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? Cancel JC; Crozat K; Dalod M; Mattiuz R Front Immunol; 2019; 10():9. PubMed ID: 30809220 [TBL] [Abstract][Full Text] [Related]
20. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Colluru VT; McNeel DG Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]